American International Group’s Entrada Therapeutics TRDA Stock Holding History

American International Group’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,546	Closed	-$149K	–	2501
2024 Q1	$149K	Sell	10,546 -90	-0.8%	-$1.27K	﹤0.01%	2307
2023 Q4	$160K	Sell	10,636 -43	-0.4%	-$637	﹤0.01%	2290
2023 Q3	$169K	Buy	10,679 +380	+4%	+$5.98K	﹤0.01%	2219
2023 Q2	$156K	Buy	+10,299	New	+$142K	﹤0.01%	2318
2022 Q2	–	Sell	-5,223	Closed	-$49K	–	3263
2022 Q1	$49K	Buy	5,223 +356	+7%	+$3.82K	﹤0.01%	2849
2021 Q4	$83K	Buy	+4,867	New	+$118K	﹤0.01%	2804

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

American International Group's TRDA Position: Q2 2024 in Review

American International Group sold out of Entrada Therapeutics (TRDA) in Q2 2024, closing a stake of 10,546 shares — an estimated $149K sold.

American International Group first reported a position in TRDA in Q4 2021 and held it in 6 quarters. The position peaked at $169K in Q3 2023. 84 funds tracked by Wall St. Rank hold TRDA as of Q2 2024.

American International Group reported no remaining Entrada Therapeutics position as of Q2 2024 after selling out during the quarter.
American International Group sold 10,546 Entrada Therapeutics shares in Q2 2024, an estimated $149K.
American International Group first reported a position in Entrada Therapeutics in Q4 2021 and held it in 6 quarters.
American International Group's Entrada Therapeutics position peaked at $169K in Q3 2023.
84 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.